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Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Abstract: Removal of blood-based additives from recombinant clotting factor concentrates 
continues to be advocated by the hemophilia community due to the history of infectious disease 
transmission with previous blood-derived clotting factor concentrates. In 2003, octocog-
alpha, antihemophilic factor (recombinant), plasma/albumin-free method (ADVATE®) was 
introduced, providing the ﬁ  rst third-generation recombinant factor VIII (rFVIII) concentrate. 
Completed clinical trials have demonstrated ADVATE® to be safe and effective in adult and 
pediatric subjects utilizing both prophylactic and on-demand treatment regimens, and for 
perioperative hemostatic coverage. In the ﬁ  ve completed studies involving more than 200 
previously treated patients (PTPs), a single incidence of low-titer, non-persistent inhibitor 
was reported. Active post authorization safety surveillance (PASS) is being performed to 
expand the efﬁ  cacy and safety proﬁ  le of ADVATE® in routine clinical practice. Laboratory 
studies have documented the storage and post-reconstitution stability of ADVATE®, con-
ferring the desired versatility for home treatment. The evolving real-world experience and 
ongoing studies will provide further insight into ADVATE® pharmacokinetics, alternative 
prophylactic dosing regimens, methods for perioperative hemostatic management, and utility 
in immune tolerance induction. Experience with ADVATE®, and its place in today’s treatment 
paradigm, is the focus of this article.
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Introduction to the management of hemophilia
Hemophilia A is an X-linked bleeding disorder that results from insufﬁ  cient levels 
of factor VIII (FVIII) coagulant activity and is characterized by a prolonged clotting 
time, most often measured by the activated partial thromboplastin time. Patients 
with severe disease (FVIII levels 1%) may present with spontaneous bleeding into 
joints, muscles, internal organs, or subsequent to trauma or surgery. Such bleed-
ing episodes, if left untreated, result in serious complications including permanent, 
disabling joint, muscle, and nerve damage, loss of musculoskeletal function, or even 
death (Arun and Kessler 2000; Hilgartner 2002). Over the last century, hemostatic 
therapy for hemophilia A has evolved from using whole blood transfusion to that of 
highly puriﬁ  ed plasma-derived FVIII (pdFVIII) concentrates, and in the last 15 years, 
recombinant FVIII (rFVIII) concentrates. With each advancement in therapy, the 
quality of life for affected individuals has improved.
FVIII concentrates are commonly used on-demand (to treat bleeding episodes), 
prophylactically (planned regular infusions for prevention or suppression of bleeding 
episodes or utilized to interrupt a bleeding pattern), and to provide hemostatic cover-
age during and after surgical procedures. With each generation of FVIII concentrates, 
new features have been introduced to improve pathogen safety and convenience. Vascular Health and Risk Management 2006:2(4) 465–475
© 2006 Dove Medical Press Limited. All rights reserved
465
REVIEW
Leila Fernandes Araujo
Alexandre de Matos Soeiro
Juliano Lara Fernandes
Antônio Eduardo Pesaro
Carlos V Serrano Jr
Heart Institute (InCor), University
of São Paulo, School of Medicine,
Brazil
Correspondence: Carlos V Serrano Jr
Coronary Care Unit, Av. Dr. Enéas
Carvalho Aguiar, 44 – sala 12 – bloco 2,
São Paulo - SP - 05403-900, Brazil
Tel +55 11 3069 5058
Fax +55 11 3088 3809
Email carlos.serrano@incor.usp.br
Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
Keywords: coronary artery disease, women, risk factors, prevention, diagnosis, treatment.
Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
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incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
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Advancements in therapy have made patients less dependent 
on treatment centers and provided them increased control 
of their disorder (Dunn and Abshire 2006).
A major complication in hemophilia management today 
is the development of inhibitors, antibodies that neutralize 
the infused FVIII. Inhibitors most often emerge within 
the ﬁ  rst 50 exposure days (ED) of replacement therapy in 
patients with severe hemophilia A (Key 2004). Although 
inhibitor incidence greatly decreases after this initial high-
risk period, the risk does not reach zero and persists to 
some small degree throughout life (Kempton et al 2006). 
The immunogenicity of new clotting factor concentrates 
is evaluated in studies with previously treated patients 
(PTPs) that have demonstrated tolerance to FVIII through 
an extensive history of prior exposure to licensed products 
(ie, 100–150 previous ED) without inhibitor development 
(White et al 1999).
In contrast, the rate of inhibitor development in previ-
ously untreated patients (PUPs) or minimally transfused 
patients is approximately 25%–30% (Lusher 2000). Studies 
and registries of various sizes and rigor in PTPs, who have 
demonstrated tolerance to FVIII therapies, have reported an 
inhibitor incidence of 1%–3% (Key 2004).
Inhibitor kinetics and persistence vary; they are mea-
sured and quantified by the Bethesda assay (Kasper et al 
1975) in the form of Bethesda units (BU). An estimated 
20%–55% of all inhibitors disappear spontaneously 
without specific intervention; these inhibitors tend to 
be low titer and are defined as transient. Inhibitors that 
persist are divided into two main categories based upon 
the highest BU level achieved; low titer inhibitors are 
those that have titers 5BU despite repeated exposure to 
FVIII concentrate whereas high responding inhibitors are 
those whose historical titer is 5BU and often rise after 
repeat exposure, a phenomenon called anamnesis. Patients 
with low titer inhibitors are often continued with FVIII 
concentrates in doses sufficient to achieve a hemostatic 
level and control bleeding (DiMichele 2002). Patients 
with higher titer inhibitors may become tolerant to FVIII 
following treatment on immune tolerance programs often 
utilizing prolonged periods of intensive FVIII therapy 
(Wight et al 2003). In some cases, however, immune 
tolerance is either not utilized or fails, and the inhibitor 
persists indefinitely; these patients are most often treated 
with bypassing therapies, agents that achieve hemostasis 
through alternative mechanisms to obtain bleed control. 
Bypassing agents, although highly effective in treating 
bleeding episodes, are not uniformly effective, leaving 
this population at risk of increased morbidity and mortal-
ity (Astermark et al 2007).
History of pathogen transmission 
and the need for blood-free 
recombinant FVIII technology
The pathogen transmission safety record of factor concen-
trates used to manage hemophilia continues to be a major 
concern both for those receiving and prescribing these 
therapies. In the 1980s, many people with hemophilia were 
infected with HIV and/or hepatitis C (HCV) through the use 
of contaminated plasma derived clotting factor concentrates. 
As a result, the life-span for those with hemophilia who con-
tracted these blood borne pathogens was negatively impacted, 
increasing their morbidity and mortality (Arnold 2006). 
Today, an estimated 30% of people with hemophilia between 
the ages of 21–60 years are infected with HIV (CDC 2005). 
As a consequence, a number of safety measures including 
enhanced donor screening tests and procedures, and the intro-
duction of viral inactivation and removal technologies, have 
been implemented to address blood-borne disease in plasma 
based therapies. The desire for therapies with the highest 
degree of safety has remained a driving force in therapeutic 
research and development. As a result, a variety of rFVIII 
products have been developed as safer alternatives to prevent 
transmission of potential emerging pathogens.
In 2006, the FDA released a statement that the risk of 
acquiring variant Creutzfeld-Jakob Disease (vCJD) is low, but 
could not be deemed to be zero, in people using US-licensed 
pdFVIII products (FDA 2006). Based on these conclusions, the 
Great Lakes Hemophilia Foundation (GLHF) recommended 
that physicians and patients consider this risk when choosing 
an appropriate therapy (Medical Advisory #406 2006). To 
this end, the National Hemophilia Foundation Medical and 
Scientiﬁ  c Advisory Council (MASAC) also recommended 
recombinant FVIII products as the treatment of choice for 
patients with hemophilia A (MASAC #177 2006). The UK 
Department of Health independently created a “Recombinant 
for All” policy to ensure that hemophilia patients have access 
to the safest treatments (UKHCDO 2003). Similar policies 
are now in effect in a number of countries, including Austria, 
Germany, Ireland, the Netherlands, Australia, and Canada 
(AHCDC 2006; EHC 2006; NH 2006).
To date, there have not been any documented viral- 
or prion-based disease transmission reports from rFVIII 
products (Dunn and Abshire 2006). Despite the excellent 
safety record of rFVIII therapeutics, the risk for potential 
transmission of blood-borne infectious agents through the Vascular Health and Risk Management 2006:2(4) 465–475
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use of human- or animal-derived plasma proteins in rFVIII 
concentrates remained a concern. No current viral inactiva-
tion/elimination method, such as solvent/detergent methods 
or heat treatment, is infallible (Brown 2001; Hoots 2001; 
Llewelyn et al 2004). For example, three viruses are known 
to be a potential threat to the supply of blood and blood prod-
ucts; hepatitis A (HAV) is resistant to the solvent/detergent 
viral inactivation step, parvovirus B is both heat and solvent/
detergent resistant, and transfusion transmitted virus (TTV) is 
resistant to heat, detergent, and disinfectants (Valentino and 
Oza 2006). Despite the present use of effective pathogen inac-
tivation methods, international guidelines recommend that 
manufacturers make all efforts to remove human and animal 
proteins, including human albumin and other plasma-derived 
proteins, from the manufacturing process of recombinant 
products, and that such differences be taken into consider-
ation when selecting an appropriate therapy (MASAC #177 
2006; UKHCDO 2003; AHCDC 2006).
Nearly all rFVIII concentrates use human- or animal-
derived plasma proteins at some point in the processing. 
Recombinant FVIII concentrates now are classiﬁ  ed into ﬁ  rst, 
second, and third generation based on the use of human- or 
animal-derived materials at various stages of processing, as 
shown in Table 1.
The ﬁ  rst-generation product relies on plasma proteins in the 
production, puriﬁ  cation, and ﬁ  nal formulation of the product 
(Jing et al 2002; Package Insert, Recombinate®, Baxter BioSci-
ence). Second-generation products use plasma-derived proteins 
in the production and/or puriﬁ  cation phase (Package Insert 
Kogenate® FS, Bayer Healthcare; Package Insert ReFacto®, 
Wyeth Pharmaceuticals, Inc), and trace levels of such proteins 
have been detected in the ﬁ  nal container of selected products 
(Eriksson et al 2001; EPAR Kogenate Bayer; EPAR Helix-
ate NexGen). In 2003, ADVATE® (Antihemophilic Factor 
[Recombinant], Plasma/Albumin-Free Method [rAHF-PFM]) 
was licensed as the ﬁ  rst rFVIII that does not include animal or 
human plasma protein additives during the cell culture, puriﬁ  ca-
tion, or formulation processes. The clinical experience of this 
full-length rFVIII is the focus of this article.
Development of the plasma/
albumin-free platform
To develop ADVATE®, the Chinese hamster ovary (CHO) 
cell line used to produce the ﬁ  rst-generation FVIII concen-
trate, Recombinate®, was adapted to grow in a proprietary 
culture medium, free of human and animal derived addi-
tives. This cell line, which co-expresses full-length FVIII 
and von Willebrand Factor (VWF), did not undergo any 
genetic manipulations, and the cDNA coding sequence of 
the recombinant proteins remained identical to those used 
for Recombinate®. To attain consistent and stable production 
of rFVIII, a continuous (chemostat) perfusion bioreactor 
culture is used to harvest the clotting factor with minimal 
environmental changes to the cell line.
The puriﬁ  cation techniques utilized for ADVATE® are 
based on the methods used for its ﬁ  rst generation prede-
cessor. First, the rFVIII-containing cell culture medium is 
ﬁ  ltered to remove the CHO cells, followed by a sterile ﬁ  ltra-
tion step. The rFVIII protein is then puriﬁ  ed in a stepwise 
fashion, using multiple chromatography columns, including 
immunoafﬁ  nity (to eliminate non-FVIII proteins) and cation 
exchange (using electrical charge differences to eliminate 
other impurities). This is followed by a solvent/detergent 
(S/D) step, a viral inactivation process which preserves the 
integrity of the structure and function of the FVIII molecule 
yet inactivates lipid enveloped infectious agents (Horowitz 
et al 1993). Following the S/D step, the eluate is further 
puriﬁ  ed using anion exchange chromatography. Finally, 
ADVATE® is pooled, frozen, and stored until ready for ﬁ  nal 
formulation, ﬁ  lling, and lyophilization.
Table 1 Commercial recombinant FVIII therapies
Generation Product    Producing Culture  Molecular Product
   cell  line  medium  FVIII  stabilizer
First Recombinate® CHO  Bovine  serum  Full-length Human
     albumin    albumin
Second Kogenate® FSb BHK  HPPSa   Full-length  Sucrose
Second Helixate® FSb BHK  HPPSa Full-length  Sucrose
Second ReFacto®  CHO  Human serum  B-domain deleted  Sucrose
     albumin
Third ADVATE® CHO  None  Full-length  Trehalose
CHO indicates Chinese hamster ovary cell line; BHK indicates Baby hamster kidney cell line. Information as indicated in respective product package inserts.
aHPPS, Human plasma protein solution consists of several human plasma proteins, including albumin.
bThe equivalent products Kogenate FS and Helixate FS are also marketed under the brand names Kogenate Bayer and Helixate Nexgen, respectively.Vascular Health and Risk Management 2006:2(4) 465–475
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The absence of human- or animal-plasma protein 
additives eliminates the risk of pathogen transmission. 
Formulation components including the sugars trehalose 
and mannitol mimic the stabilizing function of albumin and 
have been substituted to replace plasma protein stabilizers 
(Product Monograph 2004).
Preclinical evaluation
Biochemical and preclinical analyses assessed toxicity, 
tolerability, and hemostatic activity of ADVATE®. The new 
formulation was compared with its well-established prede-
cessor, Recombinate® (Bray et al 1994; White et al 1997), 
demonstrating that ADVATE® and Recombinate® have 
structural and functional equivalence (Ewenstein 2004).
The approved route of administration for ADVATE® is 
via intravenous bolus infusion; however, in speciﬁ  c clinical 
circumstances such as surgery or severe or life-threatening 
bleeding events, FVIII products are administered via continu-
ous infusion (Batorova and Martinowitz 2002). Therefore, 
the stability and feasibility of ADVATE® delivery by con-
tinuous infusion were assessed in in vitro experiments that 
simulated this clinical application (Fernandez et al 2006). In 
the presence and absence of heparin (2 U/mL), ADVATE® 
at mid- (522 IU/vial) and high-potency (1210 IU/vial) 
doses, were run through a CADD-1 infusion pump at a rate 
of 1.5 mL/minute, at 30 ºC, for 48 hours. Reconstituted 
control vials of the same lot were maintained at the same 
temperature, over the same duration. Stability and recovery 
of at least 80% of baseline potency was observed for up to 48 
hours after reconstitution and running through the CADD-1 
infusion pump at room temperature (30 ºC) both in the pres-
ence and absence of added heparin (Fernandez et al 2006). 
Additional stability tests regarding the storage conditions of 
unreconstituted ADVATE® were also performed and will be 
discussed in the “Patient perspectives” section.
Clinical study program
Five completed clinical trials have investigated the use of 
ADVATE® in the prevention and treatment of bleeding epi-
sodes in PTPs. Table 2 illustrates the studies, patients, and 
endpoints measured in these completed phase II/III clinical 
studies.
Pivotal efﬁ  cacy and safety study
Results from a three-part study investigating the use of 
ADVATE® in 10- to 65-year-old PTPs without previous 
or detectable inhibitors have previously been reported 
(Tarantino et al 2004). Double-blinded, randomized, 
crossover pharmacokinetic (PK) evaluations compared 
pilot-scale ADVATE® (produced in Orth, Austria) with 
both commercial-scale ADVATE® (produced in Neuchatel, 
Switzerland) and with Recombinate®. Fifty-six subjects were 
randomized to Part 1 of the study comparing PK parameters 
of ADVATE® with Recombinate®. Subjects with severe 
or moderately severe hemophilia A (baseline FVIII level 
2%) received an initial infusion (50 ± 5 IU/kg) of either 
ADVATE® or Recombinate® with analysis post-infusion 
per ISTH guidelines out to 48 hours. Following a wash-out 
period, subjects received a second infusion of the opposite 
product at a dose identical to the ﬁ  rst infusion administered. 
Mean post-infusion plasma FVIII activity proﬁ  les were 
almost identical across all time points (Figure 1), and the 
authors concluded bioequivalence in terms of area under the 
curve (AUC) and adjusted recovery.
Part 2 of the study was an open-label assessment of the 
efﬁ  cacy, safety, and immunogenicity of ADVATE®. One 
hundred and eight subjects (baseline FVIII level 2%) fol-
lowed a standard ﬁ  xed prophylactic regimen over a period of 
at least 75 ED. The study product was infused while the sub-
ject was in a steady (non-bleeding) state, 3–4 infusions/week 
at a dose of 25–40 IU/kg, with the speciﬁ  c dose prescribed 
by the investigator and rounded up to the nearest whole vial. 
While on this treatment regimen, 30% of subjects (n = 32) 
did not experience a breakthrough bleeding episode, while 
54% of the 510 bleeding episodes (n = 274) occurred in 70% 
of subjects (n = 75). In a post-hoc analysis, the overall bleed 
rate was correlated inversely with the degree of compliance 
with the prescribed prophylactic regimen. Subjects who were 
infused with 25 IU/kg per dose of ADVATE® for more than 
20% of prophylactic infusions, and/or those who adminis-
tered less than three infusions per week for more than 20% 
of the study (n = 37), experienced a 2.3-fold higher rate of 
Table 2 Global clinical program of ADVATE®
Study (n)  Endpoints
Pivotal (108)  Pharmacokinetics, efﬁ  cacy, safety and
  immunogenicity in PTPs
Continuationa (82)  Long-term pharmacokinetics, efﬁ  cacy,
  safety and immunogenicity in PTPs who
  completed the Pivotal study
Surgerya (59)  Efﬁ  cacy and safety in PTPs undergoing
 surgical/invasive  procedures
Pediatric (53)  Pharmacokinetics, efﬁ  cacy, safety and
  immunogenicity in PTPs 6 years old
Japanese Registry (15)  Pharmacokinetics, efﬁ  cacy, safety and
  immunogenicity in PTPs in Japan
aPatients were eligible to participate in more than one study.
Abbreviations: PTPs, previously treated patients.Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
Coronary artery disease in women: a review
on prevention, pathophysiology, diagnosis, and
treatment
A
u
t
h
o
r
 
c
o
p
y
 
o
n
l
y
Vascular Health and Risk Management 2007:3(5) 559
Octocog-alpha in the treatment of hemophilia A
bleeding when compared to subjects who complied with the 
prescribed prophylactic regimen, infusing at least 80% of the 
time with the appropriate prescribed dose (n = 70; p  0.03). 
Of the 510 bleeding episodes that occurred during the study, 
93% were resolved with 1–2 infusions of ADVATE®, and 
86% were rated as Excellent/Good hemostatic response.
Part 3 was a double-blind, randomized, cross-over 
comparison of the pharmacokinetics of pilot-scale prepared 
ADVATE® with commercial-scale prepared ADVATE® to 
conﬁ  rm bioequivalence of the product produced via two 
scales, pilot versus commericial. On completion of Part 2, 
55 subjects were randomly assigned to receive an initial 
study infusion of either pilot-scale or commercial-scale 
ADVATE® at a dose of 50 ± 5 IU/kg. Following a wash-out 
period, subjects received a second infusion of the product 
produced from the other facility. The authors concluded 
that the products from the two facilities were bioequivalent 
(Tarantino et al 2004).
Of the 108 subjects who received ADVATE® during 
this study, one subject developed a low-level titer (2.0 BU), 
non-persistent inhibitor that was not detectable at an 8-week 
follow up visit. In addition, of the 867 adverse experiences 
(AE) categorized as non-serious, only 19, reported in 7 
subjects, were judged to be possibly (n = 12) or probably 
(n = 7) related to the administration of ADVATE®. The 19 
non-serious, related AEs consisted of taste perversion (n = 3), 
headache (n = 2), fever (n = 1), diarrhea (n = 1), dizziness 
(n = 3), hot ﬂ  ashes (n = 2), abdominal pain (n = 1), lower chest 
pain (n = 1), shortness of breath (n = 1), sweating (n = 1), 
nausea (n = 1), rigors (n = 1), and itching at the infusion site 
(n = 1). No subject withdrew due to an AE related to the 
study product. None of the serious AEs were regarded as 
possibly or probably related to study medications (Tarantino 
et al 2004).
Long-term efﬁ  cacy and safety
The long-term efﬁ  cacy and safety of ADVATE® in PTPs with 
severe or moderately severe hemophilia A (baseline FVIII 
level 2%) and no previous or detectable FVIII inhibitors 
were evaluated in an open-label, two-part continuation study 
of subjects who completed the pivotal phase III ADVATE® 
study (Tarantino et al 2004). The pharmacokinetics and 
safety proﬁ  le of a single infusion of ADVATE® (50 ± 5 
IU/kg) in subjects was compared before and after 75 ED 
to ADVATE®. Safety, immunogenicity, and hemostatic efﬁ  -
cacy of ADVATE® of three different therapeutic regimens 
were evaluated: standard prophylaxis of 25–40 IU/kg, 3–4 
times a week; modiﬁ  ed prophylaxis as determined by the 
investigator; and on-demand therapy (Gruppo et al 2006). 
No clinically relevant differences were detected between 
pharmacokinetic parameters measured at the initiation of 
trial product and after 75 EDs in either the per-protocol 
(n = 22) or the intent-to-treat populations (n = 34).
Eleven of 81 subjects reported no bleeding episodes, and 
all 11 were on a prophylactic treatment regimen for 90% 
of Part 2. Seventy of 81 subjects experienced 822 bleeding 
episodes, of which 820 were treated; 88.5% of the treated 
bleeding episodes were managed with one or two infusions. 
As shown in Figure 2, annual bleed rates for patients on 
standard prophylaxis (n = 54), modiﬁ  ed prophylaxis (n = 
53), or on-demand treatment (n = 9) were 6.0, 4.8, and 18.5, 
respectively. Protocol-compliant subjects on standard pro-
phylaxis experienced lower annual bleed rates (n = 30, 4.5 
bleeds/year) compared with non-compliant subjects (n = 24, 
7.9 bleeds/year). Hemostatic efﬁ  cacy outcomes were sus-
tained throughout a median participation interval of 617.5 
days (Gruppo et al 2006).
No subjects developed a detectable inhibitor during the 
continuation study. After a combined total of 20,832 infu-
sions, 79 of 82 subjects reported a total of 506 AEs. Four 
AEs, none of which were serious, were classiﬁ  ed to be at 
least possibly related to the product, for an overall rate of 
0.02% related AEs (4 AEs/20,832 infusions). Three of these 
were considered mild (headache, dysgeusia, and elevated 
liver function tests), and one moderate (moderately severe 
migraine). Of the 11 serious AEs reported by seven subjects, 
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VIII levels (logarithmically adjusted for illustrative purposes) over time were similar 
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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none was considered related to ADVATE® treatment. The 
authors concluded that pharmacokinetic parameters and the 
safety proﬁ  le of ADVATE® were stable with long-term use 
(Gruppo et al 2006).
Efﬁ  cacy during surgical, dental, 
or other invasive procedures
Medical management during surgery is complicated for 
patients with hemophilia due to the need to attend to hemo-
static control. Surgery is commonly used to address com-
plications resulting from repeated bleeding into joints and 
muscles. Surgery may also be required to address general 
medical issues as experienced in the non-hemophilic popula-
tion. Management of hemostasis during surgical procedures 
requires the establishment and maintenance of appropriate 
target FVIII levels to prevent bleeding both during the opera-
tive, post-operative, and rehabilitative phases. Treatment 
regimens typically involve pre-, intra-, and post-operative 
administration of FVIII during hospitalization and continued 
replacement therapy following discharge dependent upon the 
length of hospitalization and the procedure performed.
The safety and hemostatic efﬁ  cacy of ADVATE® in PTPs 
(150 ED) undergoing surgical, dental, or other invasive 
procedures was assessed in a multicenter, prospective, open-
label, uncontrolled surgery study. Severe or moderately 
severe hemophilia A subjects (baseline FVIII level 2%) 
greater than 5 years of age without history or presence of 
an inhibitor were eligible to participate and were allowed 
to enroll repeatedly for distinct surgical procedures. Each 
procedure was counted individually (Negrier et al 2006).
A total of 58 subjects underwent 65 procedures. Proce-
dures were classiﬁ  ed as either major (moderate to critical 
risk and/or estimated blood loss 500 mL), minor (mild risk 
and/or estimated blood loss 500 mL), or dental. ADVATE® 
was administered by continuous infusion in 18 procedures (4 
major, 14 minor) and by bolus infusion in 47 procedures (18 
major, 21 minor, and 8 dental). Blood loss was less than or 
within the expected range compared to a normal individual 
undergoing the same procedure in 55 of 58 assessed proce-
dures, as determined by the surgeon. Intra- and postopera-
tive hemostatic efﬁ  cacy was rated “Excellent” or “Good” in 
100% (n = 61 and 62, respectively) of assessed procedures 
(Negrier et al 2006).
No serious AEs related to ADVATE® were reported dur-
ing this study. Eight non-serious AEs were considered at least 
possibly related to ADVATE®: 2 mild AEs (lymphangitis and 
pruritus), 4 moderate AEs (one decreased hematocrit, one 
hemorrhage at time of drain removal, and 2 cases of edema 
at surgical site), and 2 severe (decreased coagulation FVIII 
coincident with a central venous access device-related infec-
tion and hematoma at surgical site). No patient developed an 
inhibitor during this study (Negrier et al 2006).
Efﬁ  cacy and safety in children
The pharmacokinetics, efﬁ  cacy, safety, and immunogenic-
ity of ADVATE® in PTPs less than 6 years of age with 
severe or moderately severe hemophilia A (baseline FVIII 
level 2%) were evaluated in a pediatric PTP study. This 
open-label, multi-center, prospective, uncontrolled, two-
part study evaluated the use of ADVATE® in 53 children 
(mean age 3.1 ± 1.5 years) with previous FVIII history of 
at least 50 EDs, and without a history of an inhibitor. Part 1 
consisted of a modiﬁ  ed pharmacokinetic evaluation following 
a single 50 IU/kg infusion of ADVATE®. Part 2 evaluated the 
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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efﬁ  cacy, immunogenicity, and safety of ADVATE® in pedi-
atric PTPs while on standard prophylaxis (25–50 IU/kg, 3–4 
times/week), investigator-modiﬁ  ed prophylaxis, or on-demand 
therapy, as prescribed by the investigating physician. Mean 
plasma terminal phase half-life (9.88 ± 1.89 h) and adjusted 
in vivo recovery (1.90 ± 0.43 IU/dL per IU/kg) were lower 
in these young children compared to the adult population in 
the pivotal trial. These differences may have been inﬂ  uenced 
by methodology, including a delayed first time point in 
the pediatric patients (1 hour post-infusion), which is beyond 
the maximum peak level derived in many adult subjects in the 
pivotal trial. However, these differences may also have been 
impacted by physiological differences between young children 
and adults, as these differences were positively correlated with 
age and body mass index in the pediatric patients (Blanchette 
et al 2006; Collins et al 2006).
Bleeding episodes were infrequent in children on prophy-
laxis, possibly due to less underlying joint disease compared 
to their adult counterparts enrolled in the previously described 
trials. The majority (90.1%) of the 354 bleeding episodes 
were managed with one or two infusions of ADVATE®, and 
treatment efﬁ  cacy was rated as “Excellent” or “Good” for 
93.8% of the bleeding episodes (Blanchette et al 2006).
Participants received a combined total of 7980 infusions 
of ADVATE® over a median of 156 exposure days (range: 
14–384 days). During the study, six AEs in two subjects 
were considered to be related to ADVATE®, all of which 
were non-serious. No inhibitors were detected (Blanchette 
et al 2006).
Perioperative management 
in children
The complexity of hemostatic management during surgery 
in children is compounded by challenges related to limited 
venous access and differing pharmacokinetic patterns such 
as decreased half-life and lower AUC, Cmax, and recovery 
compared with adults (Blanchette et al 2006).
Efﬁ  cacy and safety data of ADVATE® in pediatric (16 
years of age) PTPs undergoing surgical procedures were 
collected (Shapiro et al 2006) from the surgery and pediatric 
studies described herein. The subjects had no inhibitors and 
underwent elective or emergency surgical, dental, or an oth-
erwise invasive procedure. Some individual subjects enrolled 
multiple times for separate surgical interventions; each proce-
dure was counted individually. The study product was admin-
istered per each study site’s investigator-determined standard 
of care for surgical management of hemophilia patients. 
Patients could be treated via bolus injection or continuous 
infusion, and continuous infusion could be supplemented 
with bolus injections as needed. Procedures were classiﬁ  ed 
as either major or minor as deﬁ  ned previously.
A total of 18 patients underwent 19 procedures: 2 major, 
1 moderate, 13 minor, and 3 dental procedures. Sixteen 
procedures used one or more bolus injections, and 3 used 
continuous infusion with supplemental bolus injections. 
Intra-operative efﬁ  cacy was rated as “Excellent” or “Good” 
in 100% (n = 14) of the assessed procedures. Postoperative 
efﬁ  cacy was rated as “Excellent” or “Good” in 100% (n = 15) 
of the assessed procedures (Shapiro et al 2006). As shown 
in Table 3, 13 of 14 evaluable procedures had less than, or 
were within the predicted blood loss range for an unaffected 
individual undergoing the procedure. Although one patient 
was reported to experience greater than predicted blood loss 
in one procedure, no supplemental blood or blood products 
were required to maintain hemostasis (Shapiro et al 2006).
This case series highlights some key surgical scenarios 
encountered in the pediatric management of hemophilia. 
Known differences in pharmacokinetic parameters between 
children and adults have been documented (Blanchette 
et al 2006; Tarantino et al 2004); however, the hemostatic 
assessment results of this study closely reﬂ  ect the surgical 
experience reported in PTPs between 7 and 65 years of age 
most likely due to attention to these differences through 
monitoring of levels achieved (Negrier et al 2006).
In this evaluation of pediatric patients, a total of 349 
ADVATE® infusions were administered to PTPs 16 years 
old. Six serious AEs were reported, none of which were 
related to the product. Ninety-seven non-serious AEs were 
reported, of which one was judged as related to the product 
(mild pruritus). No inhibitors were detected, and no subject 
withdrew due to an AE (Shapiro et al 2006).
Summary of clinical data
Based on data from the completed clinical studies, ADVATE® 
has been shown to be efﬁ  cacious, well-tolerated, and non-
immunogenic in adult and pediatric PTPs with hemophilia 
A. When used prophylactically, on-demand, as well as peri-
operatively, ADVATE® was effective in preventing and/or 
controlling bleeding events (Tarantino et al 2004; Blanchette 
et al 2006; Gruppo et al 2006; Negrier et al 2006; Shapiro et al 
2006). As expected, annual bleed rates were lower in subjects 
using ADVATE® prophylactically, especially in those adherent 
to prescribed regimens, compared to an on-demand treatment 
regimen (Tarantino et al 2004; Gruppo et al 2006).
The comprehensive clinical program for ADVATE® is 
illustrated in Figure 3. This current report focuses on the Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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completed studies in large cohorts of patients. Future work 
will focus on the ongoing Phase IV studies investigating dose 
responses, prophylactic outcomes, and comparative surgical 
outcomes in PTPs, as well as use in PUPs.
Safety and tolerability
The risk of inhibitor development with ADVATE® has been 
evaluated in a broad range of therapeutic settings and in patient 
groups that represent somewhat different inhibitor risk proﬁ  les. 
Data compiled from 5 completed clinical trials and registries 
include 208 unique PTPs, 198 of which had 10 ED and/or 
6 months of observation during the study. Of these, one low-
titer, non-persistent inhibitor was detected in one subject, for 
an overall incidence rate of 0.51% (95% conﬁ  dence interval 
0.03%–2.91%) (Unpublished data, Baxter BioScience). 
An on-going prospective post-licensure safety surveillance 
study designed to evaluate the ﬁ  rst full year experience of 
new patients on ADVATE® will continue to accumulate data 
regarding the immunogenicity in a larger hemophilia popula-
tion, including patients with mild or moderate hemophilia A, 
as well as patients with a history of inhibitor development. 
Thus, this study may provide a more accurate estimate of the 
incidence of inhibitors in real world practice.
Inhibitor management
Immune tolerance induction (ITI) in patients with inhibitors 
has been reported to be successful in a number of cases using 
ADVATE®. In one study, 3 PUPs (13–16 months of age) who 
Table 3 Predicted and actual blood loss associated with surgical procedures
     Average-maximum
Procedure  Actual blood loss (mL)  Predicted blood loss (mL)
Ross procedure  50  200–2000
Axillary mass excision  50  N/D
Arthroscopie knee synovectomy  50  50–250
Port-a-cath removal  100  15–50
Port-a-cath removal and excision of seroma  8  5–10
Elbow synovectomy  20  30–100
Inferior oblique myectomy  0  0.5–1.0
Arthroscopic ankle synovectomy/debridement  5  10–50
Radionuclide ankle synovectomy  0  0
Dental extraction  15  5–15
Multiple teeth extraction (a)  5  5–10
Multiple teeth extraction (b)  7  20
Eye cyst excision  1  2
Central catheter removal (a)  5  5
Central catheter removal (b)  20  15–60
N/D, Not documented.
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Figure 3 Global clinical program study plan. Five Phase II/III clinical studies have been completed (dark bars), while four additional Phase IV studies are in progress as of 
2007 (hatched bars).Vascular Health and Risk Management 2006:2(4) 465–475
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Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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developed inhibitors while on ADVATE® (1 low titer inhibi-
tor patient and 2 high titer inhibitor patients) were success-
fully tolerized using ADVATE® (Recht and Shapiro 2005). 
A follow-up chart review of 9 children (23 months old) 
who developed inhibitors on various recombinant products 
documented the use of ADVATE® for ITI (Valentino et al 
2006). This report included 5 patients with low titer inhibi-
tors (5 BU), 3 patients with high titer inhibitors (5 BU) 
and 1 patient with a very high titer inhibitor (peak titer 1823 
BU). The inhibitors were successfully eradicated in 8 of the 
9 patients. Despite aggressive ITI, the inhibitor persisted in 
the patient with very high titer. No AEs were reported during 
this treatment period (Valentino et al 2006).
Patient perspectives
Hemophilia care has shifted from the paradigm of hospital 
or clinic based treatment of bleeding events to home based 
therapy utilizing diverse regimens ranging from on-demand 
to primary prophylaxis to immune tolerance induction 
(Rosendaal et al 1990). Prophylaxis as a long-term treatment 
regimen requires FVIII infusions 2–4 times per week and 
has been documented to be the best therapy for prevention 
of joint disease associated with musculoskeletal hemorrhage 
(Manco-Johnson 2003). Such a treatment regimen requires 
not only a commitment by the patient and/or caregiver, but 
requires safe and readily available infusion products; many 
of these previous barriers to prophylaxis have been addressed 
by the introduction of recombinant products. In addition 
to potential improvements in musculoskeletal outcomes, 
prophylaxis may also improve the psychosocial develop-
ment of children by eliminating the anticipatory concern 
associated with potential future bleeding events (Blanchette 
et al 2004).
FVIII concentrates that eliminate the risk of pathogen 
transmission not only increase patient conﬁ  dence in the 
safety of the product but may also have long-term economi-
cal beneﬁ  ts as well. Pharmacoeconomic models of medical 
costs associated with co-morbidities suggest that hemophilia 
patients with HIV and HCV have higher medical costs com-
pared to non-infected hemophilia patients due to increased 
hospitalization, more frequent ofﬁ  ce visits to physicians 
and specialists, and use of long-term health resources (Chan 
et al 2005; Li-McLeod et al 2006). Although these scenarios 
are speciﬁ  c to HIV and HCV, it can be hypothesized that 
similar pharmacoeconomic ﬁ  ndings might be applicable with 
possible emerging pathogens causing a chronically infected 
state. Thus, the use of therapies least likely to cause infectious 
co-morbidity may lead to avoidance cost-savings.
Patient convenience
To make home treatment practical coagulation products 
have been improved to make them more convenient, easier 
to use, and stable for longer periods of time under a variety 
of storage conditions. In addition, needle-less reconstitution 
devices have been developed for all rFVIII products. Such 
devices decrease the risk of patient or caregiver injury.
Because patients today are less reliant on hemophilia 
treatment centers, manufacturers have improved the stability 
and portability of rFVIII products to accommodate patients’ 
lifestyles. The US prescribing information for ADVATE® 
states that the lyophilized product should be stored under 
refrigeration (2–8 °C [36–46 °F]), but it may be stored at 
room temperature (up to 30 °C [86 °F]) for a period of up 
to six months, not exceeding the expiration date (Package 
Insert, ADVATE®). To test real-world treatment situations, 
additional in vitro analyses demonstrated that ADVATE® 
remains stable beyond the recommended duration of storage 
(Parti et al 2005). Samples were stored for 2 weeks at 40 °C 
prior to being stored at 5, 25, or 30 °C for up to 24 months, 
and the activity was measured at 88.9%, 85.7%, and 83.5% of 
initial activity, respectively (Parti et al 2005). Likewise, when 
cycled three times through room temperature and refrigerated 
storage, the stability of ADVATE® was maintained (Parti 
et al 2006). Although not recommended by the manufacturer, 
these studies support the stability proﬁ  le of ADVATE®.
Discussion
In response to the needs of the hemophilia community, 
ADVATE® was developed as the first third-generation 
hemophilia product with a safety and efﬁ  cacy proﬁ  le com-
parable with Recombinate® (R-FVIII, Baxter BioScience). 
The removal of blood-based additives from the entire manu-
facturing process eliminates the risk of blood borne disease 
transmission associated with such additives. All clinical 
trials completed to date demonstrate that ADVATE® is 
effective in adult and pediatric PTPs for the management of 
hemophilia A. As part of the continuing clinical program, 
four additional Phase IV studies are ongoing: 1) a PUP 
study, evaluating the pharmacokinetic parameters, efﬁ  cacy, 
and safety proﬁ  le of the product in previously untreated 
patients less than 6 years of age; 2) a dose response study, 
investigating the effect of 3 doses of ADVATE® on major 
pharmacokinetic parameters in PTPs with severe hemophilia 
A; 3) a prophylaxis study, comparing the efﬁ  cacy, safety and 
immunogenicity of ADVATE® in PTPs with moderately 
severe to severe hemophilia A during standard prophylaxis, 
alternate modiﬁ  ed prophylaxis, and on-demand regimens; Vascular Health and Risk Management 2006:2(4) 465–475
© 2006 Dove Medical Press Limited. All rights reserved
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Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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and 4) a randomized surgery study comparing the efﬁ  cacy 
and safety of ADVATE® when administered by continuous 
or bolus infusion during the intra- and post-operative setting 
of PTPs undergoing total knee replacement.
The availability of safe, effective, and convenient geneti-
cally engineered FVIII therapies has the potential to improve 
patient compliance and therefore enhance the quality of life 
for people living with hemophilia A.
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Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
Keywords: coronary artery disease, women, risk factors, prevention, diagnosis, treatment.
Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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